By Anna Rose Welch, Director, Cell & Gene Collaborative
Eye-opening. Heterogenous. Challenging. Changeable.
To Robert Hariri, CEO of Celularity; Matthew Durdy, CEO of the Cell and Gene Therapy Catapult; Beth White, CBO & SVP operations of Renovacor; and Geoffrey Glass, CEO of Kiniciti, the past year in the cell and gene therapy (CGT) manufacturing space has been all of these adjectives — and more.